Patients / public:
healthcare Prof:The U.S. food and Drug Administration has now Vandetanib for the treatment of adult patients with late-stage (metastatic) thyroid cancer, which are not for surgery and the disease, the growing or symptoms have caused.
Thyroid cancer is a cancer growth of the thyroid gland, located in the neck. Thyroid cancer includes certain types of cells, which are found in the thyroid and can occur spontaneously or part of a genetic syndrome.
About 44,600 new thyroid cancer were diagnosed in the United States in the year 2010, and as a total people died from the disease, according to the National Cancer Institute. Thyroid cancer an estimated 3 to 5 percent of all thyroid cancers represent; its estimated incidence in the United States for the year 2010 is it about 1,300 to 2,200 patients, what one of the rarer forms of thyroid cancer.
Common symptoms of thyroid cancer can cough, difficulty in swallowing, enlargement of the thyroid gland, swelling of the neck, a lump on thyroid and changes in a person are voice or hoarseness.
Vandetanib aims to thyroid cancer's ability to grow and expand. There are currently no FDA approved treatments for this type of cancer. Vandetanib is daily orally administered.
Safety and efficacy of the Vandetanib were in a single, randomized international study of 331 patients with late stage tiroide founded. Patients in the study were selected to get Vandetanib or placebo (sugar pill).
The study was developed to measure the length of time that a patient without the individual cancer progressing (progression-free survival) lived. Patients, the Vandetanib had a longer without their disease compared to patients, the placebo. Median progression-free survival was 16.4 months in the placebo group and at least 22.6 months in the Vandetanib arm. It is too early to determine, the median progression-free survival in patients with Vandetanib or to say whether they are more life treated (the overall survival) compared to patients treated with placebo.
"Des Vandetanib agreement underscores FDA's commitment to permit treatment options for patients with rare and hard to treat diseases," said Richard Pazdur, m.d., Director of the Office of oncology drug of in the FDA Center for drug evaluation and research.
Common side effects from Vandetanib use include diarrhea, rash, nausea, high blood pressure, headache, fatigue, reduced appetite, and abdominal pain (stomach). Serious side effects reported while the study found five deaths in patients with Vandetanib treated. Breathing causes of death include complications, heart failure and a bacterial infection in the blood (sepsis).
Vandetanib has been shown that the electrical activity of the heart, influence, which in some cases irregular heartbeats can cause, which can lead to death. With a risk evaluation and mitigation strategy (REMS), to inform about these serious heart risks health care professionals is Vandetanib is allowed. Only health care professionals and pharmacies certified by the Vandetanib REMS Setup program, limited distribution, can prescribe and dispense the drug. Get also let patients a FDA approved medication guide about the possible risks.
Vandetanib is marketed by AstraZeneca Pharmaceuticals LP of Wilmington, Del.. Founded in, there is no trade name for this drug at the time.
Source:
U.S. food and drug administration
Posts
1 comments: on "FDA approves new treatment for rare form of thyroid cancer"
I don't take synthetics products for my hypothyroidism. Instead I trust on natural thyroid . For me, it is very effective and there are no side effects.
Post a Comment